Eli Lilly and Company (BVMF:LILY34)

Market Cap	4.10T
Revenue (ttm)	290.19B
Net Income (ttm)	75.19B
Shares Out	n/a
EPS (ttm)	83.33
PE Ratio	54.52
Forward PE	29.65
Dividend	0.74 (0.48%)
Ex-Dividend Date	Aug 14, 2025

Volume	15,052
Average Volume	17,958
Open	153.60
Previous Close	151.05
Day's Range	152.34 - 156.91
52-Week Range	113.00 - 180.70
Beta	0.46
RSI	70.42
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD